Ultime notizie per UTime (NASDAQ:WTO) Azioni

UTime

UTime Ltd is engaged in the design, development, production, sales and brand operation of mobile phones, accessories and related consumer electronics. It also provides Electronics Manufacturing Services (EMS), including Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services, for renowned brands. The company operates in China and its products are sold globally, including Mexico, Brazil, the United States, and other emerging markets in South Asia and Africa as well as Europe. It has two in-house brands, UTime, known as its middle-to-high end label and targets middle class consumers from emerging markets; and Do, as its low- to mid-end brand, is positioned to the grassroots consumers and price-sensitive consumers in emerging markets.

Roth Capital analyst Matt Koranda reiterates Kits Eyecare (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KITS#TSX">KITS</a>) with a Buy and maintains C$22 price target.

News

Price Target

Reiteration

Analyst Ratings

TSX:KITS

Roth Capital Reiterates Buy on Kits Eyecare, Maintains C$22 Price Target

<a href="https://www.youtube.com/live/vL6PaBTA4I8">https://www.youtube.com/live/vL6PaBTA4I8</a>

General

President Trump Says Want To Have One Company For Air Traffic Control Modernization; Raytheon, IBM Will Bid

Citigroup analyst Ronald Josey maintains Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Buy and raises the price target from $325 to $415.

CVNA

Citigroup Maintains Buy on Carvana, Raises Price Target to $415

In a significant legal challenge that could reshape the future of <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">public health policy</a> in the United States, a powerful alliance of leading medical and public health organizations, including the American Academy of Pediatrics (AAP), the American College of Physicians (ACP), and the American Public Health Association (APHA), filed a lawsuit on Monday against Secretary of Health and Human Services Robert F. Kennedy Jr.
The plaintiffs contend that Secretary Kennedy has launched an &#8220;assault on science, public health, and evidence-based medicine&#8221; through unilateral and arbitrary changes to COVID-19 vaccine recommendations for children and pregnant individuals.
This unprecedented <a target="_blank" href="https://www.aap.org/en/news-room/news-releases/aap/2025/leading-medical-professional-societies-patients-sue-hhs-robert-f-kennedy-jr-for-unlawful-unilateral-vaccine-changes/?_gl=1&#x2A;12sk5li&#x2A;_ga&#x2A;NTIxOTQ2NTgyLjE3NTE5NzQ2MjA.&#x2A;_ga_FD9D3XZVQQ&#x2A;czE3NTE5NzQ2MTkkbzEkZzEkdDE3NTE5NzQ2MjYkajUzJGwwJGgw" rel="noreferrer noopener">legal action</a> seeks to halt what the coalition describes as an &#8220;existential threat to vaccination in America,&#8221; arguing that Kennedy&#8217;s directives, including the controversial dismissal of expert advisors from the CDC&#8217;s immunization committee, are endangering the nation&#8217;s long-standing, science-based vaccine infrastructure and, critically, the health of its most vulnerable populations.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/07/46256464/lawmakers-investigate-whether-pfizer-delayed-covid-19-vaccine-results-for-political-reasons" rel="noreferrer noopener">Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasons</a>
<h2 class="wp-block-heading">Lawsuit Details And Allegations</h2>
The comprehensive lawsuit, filed in the U.S. District Court for the District of Massachusetts, names the U.S. Department of Health and Human Services (HHS) and Secretary Robert F. Kennedy Jr. as defendants. The plaintiffs, which also include the Infectious Diseases Society of America (IDSA), the Massachusetts Public Health Alliance (MPHA), the Society for Maternal-Fetal Medicine (SMFM), and a pregnant physician, assert that Kennedy acted &#8220;arbitrarily and capriciously&#8221; by altering COVID-19 vaccine recommendations for children and pregnant people without scientific basis.
This follows Secretary Kennedy&#8217;s public statement in May, where he <a target="_blank" href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids" rel="noreferrer noopener">expressed pleasure at the removal</a> of the COVID-19 vaccine for healthy children and pregnant women from CDC recommended immunization schedules.
A critical aspect of the lawsuit&#8217;s complaint is Secretary Kennedy&#8217;s alleged unjust dismissal of 17 members of the Centers for Disease Control and Prevention&#8217;s (CDC) Advisory Committee on Immunization Practices (ACIP). These experts were reportedly replaced with individuals known for espousing anti-vaccine viewpoints.
Dr. Susan J. Kressly, President of the AAP, underscored the gravity of these actions, stating, &#8220;This wasn&#8217;t just sidelining science. It&#8217;s an attack on the very foundation of how we protect families and children&#8217;s health. And the consequences could be dangerous.&#8221;
The lawsuit further details a pattern of interference, including blocked CDC communications, delayed or canceled meetings of CDC and Food and Drug Administration (FDA) vaccine advisers, and the announcement of studies to investigate non-existent links between vaccines and autism.
<h2 class="wp-block-heading">Seeking Injunctions And Protecting Public Health</h2>
The plaintiffs are seeking both preliminary and permanent injunctions to reverse Secretary Kennedy&#8217;s rescissions of COVID-19 vaccine recommendations. They also request a declaratory judgment to legally pronounce these changes as unlawful. Richard H. Hughes IV, lead counsel for the plaintiffs and partner at Epstein Becker Green, voiced grave concerns, asserting, &#8220;This administration is an existential threat to vaccination in America, and those in charge are only just getting started. If left unchecked, Secretary Kennedy will accomplish his goal of ridding the United States of vaccines, which would unleash a wave of preventable harm on our nation&#8217;s children.&#8221;
The lawsuit alleges that the Directive is but one example of the Secretary&#8217;s agenda to dismantle the long-standing, Congressionally-authorized, science- and evidence-based vaccine infrastructure that has prevented the deaths of untold millions of Americans. The filing highlights that the Secretary&#8217;s dismantling of the vaccine infrastructure must end, and halting this effort begins with vacating the Directive.
<h2 class="wp-block-heading">FDA&#8217;s Internal Disagreements And Historical Legal Actions</h2>
Per a recent media report, Dr. Vinay Prasad, the U.S. Food and Drug Administration&#8217;s (FDA) top vaccine official, overruled agency scientists to limit approval of two COVID-19 vaccines, despite internal recommendations to clear <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46250723/rfk-jr-influence-evident-as-vaccine-chief-overrules-scientists-limits-covid-19-vaccine-approval" rel="noreferrer noopener">them for broader use</a>.
FDA scientists had recommended full approval for updated COVID vaccines from Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) and Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) for individuals aged 12 and older, citing favorable risk-benefit analyses.
But Prasad restricted the shots to those at higher risk, seniors and people with underlying health conditions, arguing that declining hospitalization and death rates from COVID-19 shifted the balance of risks and benefits.
While distinct from the HHS lawsuit, this report underscores a broader climate of scrutiny and debate surrounding vaccine policy.
The AAP has a history of pursuing legal action against the federal government, regardless of political affiliation. Past instances include a 1983 lawsuit against HHS regarding life-sustaining treatment for infants and separate lawsuits against the FDA in 2016 and 2018 concerning graphic warnings on cigarettes and e-cigarette regulation, respectively.
Price Action: MRNA stock is trading higher by 11% to $33.18, and NVAX stock is up 6.61% at $7.05 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46301475/coreweaves-9-billion-bet-turns-crypto-miner-into-ai-powerhouse" target="_blank" rel="noreferrer noopener">CoreWeave&#8217;s $9 Billion Bet Turns Crypto Miner Into AI Powerhouse</a></li>
</ul>
Photo by lev radin via Shutterstock

Biotech

Government

Health Care

Legal

MRNA

NVAX

Medical Groups Sue RFK Jr. For Assault On Science Over Unlawful COVID-19 Vaccine Rollbacks

Citigroup analyst Christopher Allen maintains Cboe Global Markets (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) with a Neutral and raises the price target from $230 to $245.

CBOE

Citigroup Maintains Neutral on Cboe Global Markets, Raises Price Target to $245

Roth Capital analyst Darren Aftahi downgrades Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) from Buy to Neutral and maintains the price target from $20 to $20.

Downgrades

Core Scientific, Inc. - Class A Common Stock

CORZ

Roth Capital Downgrades Core Scientific to Neutral, Maintains Price Target to $20

Citigroup analyst Alexander Hacking maintains Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) with a Neutral and raises the price target from $44 to $48.

Citigroup Maintains Neutral on Freeport-McMoRan, Raises Price Target to $48

<a href="https://www.bloomberg.com/news/articles/2025-07-08/waymo-starts-offering-teen-accounts-first-in-metro-phoenix-more-cities-later" title="https://www.bloomberg.com/news/articles/2025-07-08/waymo-starts-offering-teen-accounts-first-in-metro-phoenix-more-cities-later">https://www.bloomberg.com/news/articles/2025-07-08/waymo-starts-offering-teen-accounts-first-in-metro-phoenix-more-cities-later</a>

GOOG

GOOGL

'Waymo Begins Offering Teen Accounts, Starting in Metro Phoenix' - Bloomberg News

Roth Capital analyst Rohit Kulkarni maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $620 to $740.

Roth Capital Maintains Buy on Meta Platforms, Raises Price Target to $740

<a href="https://www.bloomberg.com/news/articles/2025-07-08/waymo-robotaxis-arrive-in-nyc-as-alphabet-unit-seeks-permit" title="https://www.bloomberg.com/news/articles/2025-07-08/waymo-robotaxis-arrive-in-nyc-as-alphabet-unit-seeks-permit">https://www.bloomberg.com/news/articles/2025-07-08/waymo-robotaxis-arrive-in-nyc-as-alphabet-unit-seeks-permit</a>

'Waymo Tests Bring NYC One Step Closer to Autonomous Taxis' - Bloomberg News

<h3>Gainers</h3>
<ul>
<li>Workhorse Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) stock increased by 66.3% to $2.91 during Tuesday's regular session. The company's market cap stands at $16.5 million. </li>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) stock rose 29.04% to $0.26. The company's market cap stands at $10.1 million. </li>
<li>Fitell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) stock moved upwards by 19.94% to $0.65. The market value of their outstanding shares is at $10.9 million. </li>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) stock rose 19.06% to $15.09. The company's market cap stands at $837.4 million. </li>
<li>MOGU (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOGU#NYSE">MOGU</a>) stock moved upwards by 17.37% to $2.5. The market value of their outstanding shares is at $17.5 million. </li>
<li>Top Win International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SORA#NASDAQ">SORA</a>) stock rose 16.58% to $7.52. The company's market cap stands at $160.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Genius Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) stock declined by 11.9% to $1.18 during Tuesday's regular session. The market value of their outstanding shares is at $95.8 million. </li>
<li>Mullen Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares decreased by 11.59% to $0.21. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) shares fell 11.27% to $1.26. The company's market cap stands at $23.2 million. </li>
<li>Yunhong Green CTI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YHGJ#NASDAQ">YHGJ</a>) stock declined by 10.61% to $0.74. The market value of their outstanding shares is at $21.7 million. </li>
<li>Alliance Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AENT#NASDAQ">AENT</a>) shares declined by 9.4% to $5.25. The company's market cap stands at $295.5 million. </li>
<li>Massimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMO#NASDAQ">MAMO</a>) shares decreased by 8.88% to $2.26. The market value of their outstanding shares is at $103.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AENT

FTEL

GDHG

MAMO

MOGU

MULN

SBET

SORA

WKHS

YHGJ

12 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) shares rose 501.8% to $3.65 during Tuesday's regular session. The market value of their outstanding shares is at $78.5 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares rose 112.18% to $7.33. The market value of their outstanding shares is at $2.5 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) stock moved upwards by 72.54% to $1.14. The market value of their outstanding shares is at $3.1 million. </li>
<li>SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) shares increased by 47.59% to $0.81. The company's market cap stands at $8.8 million. </li>
<li>Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) shares moved upwards by 37.39% to $0.47. The market value of their outstanding shares is at $14.1 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) stock rose 33.48% to $0.52. The market value of their outstanding shares is at $5.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pelthos Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTHS#AMEX">PTHS</a>) stock declined by 26.1% to $19.18 during Tuesday's regular session. The company's market cap stands at $17.1 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock declined by 21.64% to $9.05. The company's market cap stands at $315.2 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares declined by 16.93% to $2.77. The company's market cap stands at $14.6 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock declined by 16.81% to $0.72. The market value of their outstanding shares is at $3.7 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) stock fell 11.06% to $1.93. The market value of their outstanding shares is at $6.8 million. </li>
<li>Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) stock fell 10.82% to $0.27. The company's market cap stands at $5.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSGM

GTBP

MBIO

MBRX

NDRA

NIVF

PROK

PTHS

RLYB

ZVSA

12 Health Care Stocks Moving In Tuesday's Intraday Session

Bernstein analyst Ian Moore maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Outperform and raises the price target from $825 to $840.

SPOT

Bernstein Maintains Outperform on Spotify Technology, Raises Price Target to $840

<h3>Gainers</h3>
<ul>
<li>Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) stock rose 52.5% to $6.94 during Tuesday's regular session. The market value of their outstanding shares is at $156.5 million. </li>
<li>Ryde Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#AMEX">RYDE</a>) stock rose 26.6% to $0.41. The market value of their outstanding shares is at $10.9 million. </li>
<li>Laser Photonics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>) stock moved upwards by 25.59% to $3.0. The company's market cap stands at $34.1 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Alta Equipment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTG#NYSE">ALTG</a>) stock increased by 20.44% to $8.93. The market value of their outstanding shares is at $245.9 million. </li>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) shares moved upwards by 19.04% to $2.5. The market value of their outstanding shares is at $4.3 million. </li>
<li>SOS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOS#NYSE">SOS</a>) stock increased by 18.74% to $7.6. The market value of their outstanding shares is at $19.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Skyline Builders Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKBL#NASDAQ">SKBL</a>) stock decreased by 23.3% to $1.18 during Tuesday's regular session. The company's market cap stands at $46.5 million. </li>
<li>Energys Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGS#NASDAQ">ENGS</a>) shares declined by 22.24% to $1.9. The company's market cap stands at $34.7 million. </li>
<li>Intercont (Cayman) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCT#NASDAQ">NCT</a>) stock declined by 14.95% to $4.21. The company's market cap stands at $133.8 million. </li>
<li>Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) stock declined by 12.65% to $9.71. The company's market cap stands at $2.5 billion. </li>
<li>Phoenix Asia Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHOE#NASDAQ">PHOE</a>) stock declined by 12.36% to $7.8. The company's market cap stands at $192.2 million. </li>
<li>Erayak Power Solution Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAYA#NASDAQ">RAYA</a>) shares fell 11.04% to $2.66. The company's market cap stands at $134.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALTG

ENGS

IPDN

LASE

PHOE

RAYA

RYDE

SKBL

SRFM

12 Industrials Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>BTCS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCS#NASDAQ">BTCS</a>) shares increased by 76.1% to $4.93 during Tuesday's regular session. The market value of their outstanding shares is at $59.0 million. </li>
<li>Sequans Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) shares rose 71.32% to $2.45. The company's market cap stands at $36.4 million. </li>
<li>Optical Cable (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCC#NASDAQ">OCC</a>) shares moved upwards by 35.35% to $4.9. The company's market cap stands at $29.6 million. </li>
<li>Zepp Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZEPP#NYSE">ZEPP</a>) shares increased by 33.62% to $4.65. The company's market cap stands at $208.7 million. </li>
<li>Thumzup Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZUP#NASDAQ">TZUP</a>) stock increased by 21.07% to $12.35. The company's market cap stands at $96.9 million. </li>
<li>Soluna Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) shares increased by 18.73% to $0.81. The company's market cap stands at $12.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) stock declined by 17.3% to $1546.79 during Tuesday's regular session. The company's market cap stands at $45.5 billion. </li>
<li>Bit Origin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOG#NASDAQ">BTOG</a>) shares fell 13.56% to $0.22. The market value of their outstanding shares is at $15.0 million. </li>
<li>T Stamp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDAI#NASDAQ">IDAI</a>) stock fell 13.4% to $3.04. The market value of their outstanding shares is at $8.7 million. </li>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) stock decreased by 12.63% to $2.56. The company's market cap stands at $1.3 million. </li>
<li>CID Holdco (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAIC#NASDAQ">DAIC</a>) shares decreased by 11.66% to $5.72. The company's market cap stands at $179.0 million. </li>
<li>Aeva Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NASDAQ">AEVA</a>) stock declined by 11.58% to $29.73. The market value of their outstanding shares is at $1.8 billion. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEVA

BTCS

BTOG

DAIC

FICO

IDAI

SLNH

SQNS

SVRE

TZUP

ZEPP

12 Information Technology Stocks Moving In Tuesday's Intraday Session

Roth Capital analyst Rohit Kulkarni maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) with a Buy and raises the price target from $180 to $205.

Roth Capital Maintains Buy on Alphabet, Raises Price Target to $205

Bernstein analyst David Vernon maintains Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) with a Outperform and raises the price target from $267 to $271.

Bernstein Maintains Outperform on Union Pacific, Raises Price Target to $271

Trading Ideas

GILD

iShares Dow Jones US Financial Sector Index Fund

NEEPR

CNBC Halftime Report Final Trades: Synovus Financial, iShares U.S. Financial ETF, Gilead Sciences; NextEra Energy, Inc. 6.926% Corporate Units

Economist and market commentator Peter Schiff is cautioning against President Donald Trump's latest tax and spending package, saying it could do more harm than good for the U.S. economy.
<h2 class="wp-block-heading">The Wrong Direction</h2>
A day after Trump signed the bill into law during a July 4 picnic at the White House, Schiff took to social media to argue that Trump's approach is flawed. "Trump&#8217;s tax cuts, which add to budget deficits, won&#8217;t grow the economy," Schiff <a href="https://x.com/PeterSchiff/status/1941530778384597097">posted on X</a>. "Instead they&#8217;ll result in higher long-term interest rates and inflation."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Trump&#39;s tax cuts, which add to budget deficits, won&#39;t grow the economy. Instead they&#39;ll result in higher long-term interest rates and inflation. To grow an economy, tax cuts need to stimulate supply, not demand. They need to increase savings and investment, not consumer spending.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1941530778384597097?ref_src=twsrc%5Etfw">July 5, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul class="wp-block-list">
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
According to Schiff, real growth comes from policies that boost supply, not just demand. "To grow an economy, tax cuts need to stimulate supply, not demand. They need to increase savings and investment, not <a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46017365/consumer-spending-slips-but-these-niche-retail-etfs-are-defying-the-downtrend">consumer spending</a>," he wrote.
When one X user replied, "Consumer spending is what drives the economy," Schiff fired back, "Wrong, a productive economy enables consumers to spend."
Schiff's warnings follow a wave of criticism from economists who believe the bill's impact on the federal deficit and inflation could be significant.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
<h2 class="wp-block-heading">Trillions In New Deficit Spending</h2>
The Congressional Budget Office estimates Trump's newly signed bill will <a href="https://www.benzinga.com/news/politics/25/07/46263434/trump-signs-sweeping-tax-and-spending-bill-that-cbo-says-will-add-3-3-trillion-to-us-deficit-cut-health-coverage-for-11-8-million-americans">add $3.3 trillion to the deficit</a> over the next 10 years. Some economists, including Kent Smetters of the University of Pennsylvania&#8217;s Wharton School, say the U.S. was already on an &#8220;exploding debt path&#8221; even before this legislation.
"It's like the house is burning down and we're throwing in some accelerant instead of some fire extinguisher," Smetters told <a href="https://abcnews.go.com/Politics/economists-deficit-increase-trumps-bill-dangerous/story?id=123481401">ABC News</a> on Friday. "We're not too big to fail."
Former Congressional Budget Office Director Douglas Elmendorf told ABC News that the bill &#8220;will make interest rates higher and makes the risks of falling into a doom loop higher than it would be otherwise.&#8221;
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
<h2 class="wp-block-heading">Millions Could Lose Health Coverage</h2>
In addition to deficit concerns, the bill includes $1.2 trillion in cuts to Medicaid and food assistance. The CBO estimates it will result in 11.8 million Americans <a href="https://www.benzinga.com/news/politics/25/07/46263553/social-security-administration-sends-unbelievable-email-on-trumps-big-beautiful-bill-report">losing health coverage</a>.
AFL-CIO President Liz Shuler called it "the worst job-killing bill in American history," <a href="https://aflcio.org/press/releases/afl-cio-president-working-people-will-hear-truth-about-what-happened-week-washington">saying</a> it gives &#8220;a $5 trillion gift to the wealthy while stripping support from working families.&#8221;
<h2 class="wp-block-heading">Trump Defends The Bill As Pro-Growth</h2>
Despite the pushback, Trump has argued that stronger economic growth and tariff revenues will offset the cost of the legislation. &#8220;Our country is going to explode with massive growth &#8230; This bill sets us on course for enormous prosperity in the new and wonderful Golden Age of America,&#8221; Trump wrote on <a href="https://truthsocial.com/@realDonaldTrump/posts/114779394158777330">Truth Social</a> on July 1.
But many economists remain unconvinced. &#8220;Bond markets can be really, really disciplinary,&#8221; Smetters told ABC News. &#8220;If we fall into a doom loop, then the U.S. has to make dramatic cutbacks in federal benefit programs like Social Security and Medicaid and sharply raise taxes. That will be really bad for people&#8217;s standard of living.&#8221;
Read Next: Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence.&nbsp;</a>
Image: Shutterstock

Peter Schiff Says Trump's Tax Cuts 'Won't Grow The Economy.' Instead, He Warns They'll Lead To Higher Interest Rates And Inflation

Bernstein analyst David Vernon maintains Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) with a Outperform and raises the price target from $258 to $295.

Bernstein Maintains Outperform on Norfolk Southern, Raises Price Target to $295

Contracts

Press Releases

UTime Limited Partners with Dr. Ehud Baron to Pioneer AI-Driven Health Solutions

UTime Limited Announces Ambitious AI Health Strategy and Strategic Collaboration

UTime Limited to Participate in International Medical Fairs and Medical Conferences

About Circul VS: A Core Continuous Blood Pressure Measurement Technology System Developed in Partnership with Dr. Ehud Baron

UTime Signs NDA to Acquire Monkeypox Vaccine Maker Bowen Therapeutics Inc and Supports Completion of FDA Registration of Related Vaccines

Remarkable Announcement on Significant Fluctuation of the UTime's Share Price

Markets

UTime Limited Announces 1-For-25 Reverse Share Split

UTime Limited Announces Pricing of $5 Million Registered Direct Offering

UTime Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

Comments

UTime

Notizie

Ultime notizie per UTime (NASDAQ:WTO) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO